Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cardiometabolic Disease Market size was over USD 192.9 billion in 2024 and is estimated to reach USD 2675.2 billion by the end of 2037, expanding at a CAGR of 24.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of cardiometabolic disease is evaluated at USD 240.1 billion.
The rising burden of global cardiovascular diseases (CVDs) is significant evidence of the fueling cardiometabolic disease market. The need for cardiac interventions and therapeutics has notably increased due to widespread hypertension and obesity. According to a study report from IQVIA, the impact of cardiometabolic diseases on the quality of life caused 334 million disability-adjusted life years (DALYs) across the world in 2021. The report further stated that in the same year, the biggest increment in DALYs was registered for atrial fibrillation, diabetes, hypertensive heart disease, and chronic kidney disease, ranging from 42% to 78% since 2006. Thus, the heightened prevalence and mortality rates are dragging a large part of the healthcare initiatives taken by the regional authorities in this sector.
As a result of having a close association with the most found causes worldwide, the cardiometabolic disease market is further expanding with meticulous efforts from government and private organizations. Their initiatives and promotional activities have helped this sector gain massive popularity among both consumers and pharma & MedTech companies, attracting more investments. According to a Research Nester report, the global cardiometabolic drugs industry alone gained USD 56.3 billion in 2024. It is further expected to be emphasized to USD 62.0 billion by 2025 and USD 123.1 billion by 2037, attributable to the rising cases of related chronic conditions such as stroke, cancer, and diabetes. Moreover, innovations in this sector have a high influence on obtaining better financial outputs.
Cardiometabolic Disease Sector: Growth Drivers and Challenges
Growth Drivers
- Advancements in preventive healthcare and early detection: Integration of tech-based diagnostic and treatment progress evaluation for early interventions has cultivated new opportunities for the cardiometabolic disease market. As the trend of digitalization gains traction in healthcare, the focus on prevention and disease identification is garnering a distinguished genre in this sector. For instance, in July 2024, WELL Health Technologies launched an AI-powered co-pilot, WELL AI Decision Support in collaboration with HEALWELL. This is designed to offer enhanced detection capabilities to cardio professionals for high-risk CVD patients, opening the scope for a wide range of treatment options such as therapies and drugs.
- Strategic R&D collaborations and partnerships: Growing incidences have created a demanding consumer base for the cardiometabolic disease market. Thus, continuous evolution in offerings is needed to retain an uninterrupted supply, widening product versatility. This inspired global leaders to elevate their R&D progress by possessing each other’s capabilities, leading to strategic agreements. For instance, in January 2024, Novo Nordisk collaborated with Omega Therapeutics and Cellarity to bring innovative treatments for this condition. The company offered a maximum limit of USD 532 million for each pioneering medicine while providing R&D reimbursement to access their assets to develop epigenomic controllers and small molecule therapies.
Challenges
- Limited access to adequate healthcare facilities: Establishing footprints in the cardiometabolic disease market of low- and middle-income regions is a challenge due to the absence of proper medical infrastructure. Many organizations from these landscapes still lack complete utilization of advanced diagnostic and treatment solutions, adhering to the limitation in patients’ knowledge about this disease. The economic barrier and poor healthcare system may further restrict the sector’s reach to a major portion of the global population, constraining market expansion.
- Stringent regulatory hurdles: In addition to the affordability issues in the cardiometabolic disease market, the elongated procedures for regulatory approvals may dilute the interest of participants. The complexity of disease management often creates doubts about the effectiveness and safety of available regimens. This may cause delays in receiving acceptance from different strict regulatory frameworks, hindering the flow of product supply in this sector. It also affects the strategies for globalization by raising a need for non-beneficial alterations in the plan.
Cardiometabolic Disease Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
24.5% |
|
Base Year Market Size (2024) |
USD 192.9 billion |
|
Forecast Year Market Size (2037) |
USD 2675.2 billion |
|
Regional Scope |
|
Cardiometabolic Disease Segmentation
Treatment (Angiotensin-converting Enzyme (ACE) Inhibitors, Diuretics, Glucophage)
Angiotensin-converting enzyme (ACE) inhibitors segment is set to account for cardiometabolic disease market share of around 43.5% by 2037. ACE inhibitors are widely accepted for their pivotal role in managing hypertension, which is the major cause of this disease. According to a WHO report, the global population of 30 to 79-year-old patients with hypertension reached 1.2 billion in 2023, making the segment’s position more prominent. Government efforts to control CVD inflation across the world due to the increasing cases of hypertension are also fueling this segment. For instance, in December 2022, the WHO/Europe Signature Initiative was launched for CVD burden reduction through hypertension control.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
In terms of distribution channels, the hospital pharmacies segment is expected to hold the largest share of the cardiometabolic disease market by the end of 2037. This segment’s growth is pledged by the widespread network of hospitals and frequently visiting patients. The pharmacies present in the hospital premises are well-stocked with all required medications, making them the prime target for pharma companies to capture. In addition, the improved in-patient and out-patient services ensure medicine purchases from these sources, particularly in developed regions. According to a 2022 survey conducted by NLM on hospitals in the European Union countries, around 20-50% of total third-party buyer spending goes to the hospital pharmacies of Europe.
Our in-depth analysis of the global market includes the following segments:
|
Treatment |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCardiometabolic Disease Industry - Regional Synopsis
North America Market Analysis
North America in cardiometabolic disease market is anticipated to hold over 46.3% revenue share by the end of 2037. The progressive healthcare infrastructure of this region is fed by continuous R&D initiatives and increasing healthcare expenditures. The assured access to advanced treatment and diagnosis further accumulates a well-established scenario for leaders of this sector. For instance, in July 2023, Eli Lilly and Company purchased Versanis to solidify its position in North America by acquiring rights for bimagrumab manufacturing and marketing. Moreover, the prioritized activities in reducing heart-related mortality cases across the region are driving growth in this field.
The U.S. is garnering a suitable atmosphere for the cardiometabolic disease market with a supportive regulatory framework and growing CVD incidences. The rising population of obese and diabetic patients throughout the country is becoming a major public health concern. This is further attracting global leaders to participate in this marketplace. For instance, in March 2024, Novo Nordisk received a supplemental New Drug Application (sNDA) approval from the FDA for Wegovy (semaglutide) injection. The acceptance by the U.S. standards made this drug a revolutionary solution for major cardiac risk reduction in both overweight adults and diagnosed CVD patients.
Government funding works as a financial cushion for the Canada cardiometabolic disease market. The well-proportionated healthcare governance of this country is a great influential factor for this sector. Their strategies to make cardio care more accessible to every patient through spreading awareness about early prevention and intervention for better patient outcomes have inflated the demand for advanced treatment and diagnostic solutions. For instance, in May 2022, the Health Ministry of Canada allocated USD 5.0 million for implementing an improved healthcare system for heart failure patients. The pan-Canadian national heart failure research network was built to develop better treatment plans and drugs.
APAC Market Statistics
Asia Pacific is expected to register the fastest growth in the cardiometabolic disease market during the period, i.e. 2025-2037. Similar to the developed regions, APAC is also driven by major growth factors including the rise in CVD cases and the presence of pharma giants. It is further fostering business opportunities for more diversely categorized solution providers to secure lucrative profit margins. For instance, in November 2024, the Cardiovascular Disease National Collaborative Enterprise (CADENCE) and Medera collaboratively commenced clinical trials for a ground-breaking multi-center gene therapy product. Both companies set their goals to captivate the emerging HF market of Asia by introducing such innovations.
India is revolutionizing the cardiometabolic disease market with the penetration of advanced technologies. In addition, the governing bodies of this country are proactively promoting early diagnosis and prevention measures for this condition. They are meticulously drafting plans to increase the availability of all treatment and detection methods for such heart-related chronic diseases. For instance, in June 2024, the Council of Scientific and Industrial Research (CSIR) commenced a pan-India longitudinal study on the rising burden of cardiometabolic diseases in India. The purpose of this study was to deliver the required collective data for developing an enhanced predictive and personalized healthcare model.
The growing CVD population and ongoing clinical discoveries are collectively propelling the China cardiometabolic disease market. The country is highly focused on enlarging its domestic production of innovative therapeutics, creating favorable trading situations for both local and international medicine suppliers and developers. Furthermore, the enlarged pharma industry is igniting progress in this landscape. According to the International Trade Administration report, the pharmaceutical industry accounted for USD 161.8 billion in 2023, which contributed to 30% of the total global output.
Companies Dominating the Cardiometabolic Disease Landscape
- Cardax, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Novo Nordisk A/S
- Eli Lilly and Company
- Bayer AG
- Allergan
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Marea Therapeutics
The highly competitive dynamics of the cardiometabolic disease market are pushing global leaders to attain maximum R&D support and resources to introduce new product lines. They are integrating advanced technologies to accelerate the speed of the drug development process. For instance, in September 2023, Novo Nordisk unveiled LAB eN² in collaboration with Evotec SE to fasten transitional drug discovery for cardiometabolic disease. The unique engagement model is designed by combining both company’s capabilities in multimodal, pre-clinical, clinical, and commercial aspects. This model also includes the academic consortium of Harvard University, Mass General Brigham, and Beth Israel Deaconess Medical Center. Such key players are:
In the News
- In January 2025, Novo Nordisk extended its partnership with Valo Health, Inc. to bring innovative and novel solutions for this market by utilizing AI-based data. The agreement covered the expansion of Novo’s R&D on a total payment of USD 4.6 billion for Valo’s upgraded Opal Computational Platform, R&D funding, and royalty.
- In June 2024, Marea Therapeutics announced the release of capital worth USD 190 million for a combined series A and B financing, led by Third Rock Ventures and Sofinnova Investments respectively. The investment was aimed to accelerate the development of next-generation drugs for cardiometabolic diseases.
Author Credits: Radhika Pawar
- Report ID: 7052
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT
